Company

Pleasanton, CA

4300 Hacienda Drive
Pleasanton, CA 94588

Headquartered in Pleasanton, California, the Roche Sequencing Unit is focused on developing novel sequencing technologies and products to support innovation in clinical research applications. Our site is developing assays for sequencing, and refining sequencing techniques to advance sequencing technologies that will deliver truly differentiated clinical value.

Belmont, CA

1301 Shoreway Road, Suite 300
Belmont, CA 94002

www.bina.com
Bina Technologies builds next-generation technologies for scalable and accurate processing and management of genomic information. Bina’s Genomic Management Solution is an integrated, scalable, and comprehensive analysis platform that empowers clinical and translational researchers to gain insight from their genomic data sets. Bina’s Genomic Management Solution dramatically decreases the complexity, time, and cost of genomic analysis, accelerating the science of personalized medicine.

Cape Town, South Africa

271 Victoria Road
Salt River, Cape Town 7925
South Africa

Kapa Biosystems is a life science reagents supplier that employs proprietary, directed evolution technologies to optimize enzymes for PCR, real-time PCR, next-generation sequencing and molecular diagnostic applications. Kapa Biosystems offers a portfolio of best-in-class products containing novel enzymes that confer significant performance advantages when compared to traditional wild-type enzymes.  The company is based in Wilmington, Massachusetts with a research, development and manufacturing facility in Cape Town, South Africa.

Madison, WI

500 S Rosa Road
Madison, WI 53719

Roche NimbleGen, an innovator in genomics, is focused on developing target enrichment solutions for next-generation sequencing. Our technologies allow researchers to selectively target DNA or RNA sequences of interest in human or non-human genomes, either through focused exomes, transcriptomes or custom designed gene panels for variant discovery and validation. With our ever growing suite of tools for targeted DNA sequencing, we are enabling the life science community to achieve their research goals more efficiently in order to understand the association genomics and epigenomics have with diseases and biological processes.

Potsdam, Germany

Hermannswerder 20 A
14473 Potsdam

www.signature-diagnostics.eu/en/
Signature Diagnostics AG is a translational oncology and genomics company based in Potsdam, Germany. Founded in 2004, Signature develops large tumor tissue and plasma biobanks in multiple cancers, including colorectal and lung cancer in the framework of large multicenter prospective clinical studies. A key aspect of the translational oncology work is Signature's biobanks with longitudinal plasma samples from cancer patients. The company also develops several next generation sequencing (NGS) assays using targeted gene panels. Signature has expertise in developing ultra-deep sequencing tests utilizing cfDNA, which may advance the development of non-invasive treatment response monitoring for cancer patients.

Santa Clara, CA

2841 Scott Blvd.
Santa Clara, CA 95050

Genia Technologies, Inc. was founded in March 2009. Genia is developing a potentially disruptive next generation sequencing technology with integrated circuits enabling massively parallel, single-molecule DNA sequencing. Its versatile nanopore-based platform allows for single molecule, electrical real-time analysis without the need for complicated optics, labels, amplification, or fluidics. The heart of Genia's technology is a semiconductor integrated circuit where an automated assembly of nanopores in a lipid bilayer allows for the measurement of single molecules. Genia's sensor technology and its proprietary NanoTag chemistry enables accurate base calls, overcoming many of the limitations faced by other nanopore-based sequencing efforts.

San Jose, CA

5945 Optical Court
San Jose, CA 95138

www.ariosadx.com
Ariosa Diagnostics, Inc. is a leading global molecular diagnostics company committed to improving overall patient care by developing and delivering innovative, affordable, and widely-accessible testing services through their CLIA laboratory. Tests are fully validated to CLIA requirements by rigorous and comprehensive methodologies, to ensure health care practitioners and patients can be confident in the test’s performance. Ariosa has developed leading-edge technologies to perform a directed analysis of cell-free DNA in blood. The company is headquartered in San Jose, California.